全文获取类型
收费全文 | 10457篇 |
免费 | 845篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 388篇 |
妇产科学 | 283篇 |
基础医学 | 1391篇 |
口腔科学 | 132篇 |
临床医学 | 1681篇 |
内科学 | 1686篇 |
皮肤病学 | 184篇 |
神经病学 | 1075篇 |
特种医学 | 253篇 |
外科学 | 970篇 |
综合类 | 131篇 |
一般理论 | 22篇 |
预防医学 | 1411篇 |
眼科学 | 260篇 |
药学 | 761篇 |
中国医学 | 11篇 |
肿瘤学 | 635篇 |
出版年
2024年 | 13篇 |
2023年 | 125篇 |
2022年 | 159篇 |
2021年 | 312篇 |
2020年 | 241篇 |
2019年 | 383篇 |
2018年 | 398篇 |
2017年 | 304篇 |
2016年 | 309篇 |
2015年 | 347篇 |
2014年 | 454篇 |
2013年 | 632篇 |
2012年 | 887篇 |
2011年 | 822篇 |
2010年 | 442篇 |
2009年 | 375篇 |
2008年 | 634篇 |
2007年 | 645篇 |
2006年 | 592篇 |
2005年 | 597篇 |
2004年 | 554篇 |
2003年 | 516篇 |
2002年 | 428篇 |
2001年 | 88篇 |
2000年 | 57篇 |
1999年 | 86篇 |
1998年 | 91篇 |
1997年 | 71篇 |
1996年 | 66篇 |
1995年 | 57篇 |
1994年 | 55篇 |
1993年 | 54篇 |
1992年 | 34篇 |
1991年 | 37篇 |
1990年 | 25篇 |
1989年 | 20篇 |
1988年 | 27篇 |
1987年 | 25篇 |
1986年 | 21篇 |
1985年 | 16篇 |
1984年 | 22篇 |
1983年 | 18篇 |
1982年 | 28篇 |
1981年 | 17篇 |
1980年 | 18篇 |
1979年 | 15篇 |
1978年 | 20篇 |
1975年 | 16篇 |
1974年 | 18篇 |
1973年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
3.
4.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献
5.
6.
7.
8.
McArdle's disease with myoadenylate deaminase deficiency: observations in a combined enzyme deficiency 总被引:1,自引:0,他引:1
Exercise and work potential of a patient with coexistent myophosphorylase and myoadenylate deaminase (AMPDA) deficiency was compared with that of three patients with myophosphorylase deficiency alone. The patient with the combined defect failed to produce an abnormal rise in serum ammonia or hypoxanthine as seen in the other patients after forearm exercise. Maximum oxygen consumption and work rates during cycle ergometer testing were similar in all patients, but well below controls. The occurrence of two defects involving short-term energy metabolism in muscle presents an opportunity to define further the metabolic role of AMPDA. 相似文献
9.
10.